George Rathmann, first CEO of Amgen, dies in Ca. - Yahoo Finance

As CEO of Amgen from 1980 to 1988, he developed two blockbuster drugs that made the company's name and have remained its best sellers: Epogen for anemia and Neupogen for cancer patients undergoing chemotherapy. "George Rathmann was a ...

Need WBC count advise. - American Cancer Society

My husband ended his 5FU 6 months ago. He had issues with a drop in his WBC counts. He took Neupogen for the last two months of treatments. The Neupogen substantially raised his counts over 15. Had one of his first blood tests today and his WBC count was ...

Amgen Beats but Maintains Outlook - Yahoo Finance

Worldwide revenues of Neulasta and Neupogen grew 9% to $1,344 million in the first quarter. An increase in average net sales price and unit demand boosted US revenues to $1,053 million, up 13%. International revenues, however, continued to ...

Royalty Pharma Raises $600 Million of Debt - msnbc.com

Leading products in Royalty Pharma's portfolio include: Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan ...

Antares Reports A Modest Reassuring Advancement - Seekingalpha.com

Antares (AIS) almost broke even in Q1 2012 as the company reported: Net loss was approximately $0.1 million and $1.4 million for the first quarters of 2012 and 2011, respectively, and net loss per share was $0.00 and $0.02 in the first quarters of 2012 and ...

RNCOS Releases a New Report - G-CSF Biosimilars Market Forecast to 2015 - SBWire

In 2010, the G-CSF biosimilars had a 33% share in the global biosimilars market. It is expected that the patent expiries of Neupogen (filgrastim) in 2013 and Neulasta (pegfilgrastim) in 2015 will make the way for the entry of G-CSF biosimilars ...

South Africa: Cancer Services Take Strain in Gauteng - AllAfrica.com

bioscrub and savlon (all disinfectants); and neupogen (generates specific white blood cells in patients on chemo with low white cell counts). Chemotherapy patients were also turned away last week after being told their drugs were out of stock at the time.

4 Interesting Top-Growth Stocks By Richard Snow - Seekingalpha.com

Whereas the U.S. biosimilar approval guidelines are still in the last stage, Teva has already filed an application in the U.S. for a biosimilar version of Amgen's Neupogen. Teva and others have had mixed success and slow market share profits with their ...

Slow, costly process stymies generic biotech drugs - msnbc.com

U.S. patent expirations for biotech drugs will occur in 2013 for Epogen and another Amgen drug, white blood cell booster Neupogen. The FDA said in early February it had held discussions for a total of 35 potential biosimilar products ...